ABL1 and acute lymphoblastic leukemia: B-ALL with BCR::ABL1-like features is now an entity (previously a provisional entity), by definition sharing gene expression and phenotypic features of B-ALL with BCR::ABL1 fusion; it is prevalent across all age groups [13, 14] and shows significant benefit from targeted therapies [15–17].